CA2216696A1 - Polysaccharide-bound nitric oxide-nucleophile adducts - Google Patents

Polysaccharide-bound nitric oxide-nucleophile adducts

Info

Publication number
CA2216696A1
CA2216696A1 CA002216696A CA2216696A CA2216696A1 CA 2216696 A1 CA2216696 A1 CA 2216696A1 CA 002216696 A CA002216696 A CA 002216696A CA 2216696 A CA2216696 A CA 2216696A CA 2216696 A1 CA2216696 A1 CA 2216696A1
Authority
CA
Canada
Prior art keywords
nitric oxide
polysaccharide
bound nitric
releasing
polymeric composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002216696A
Other languages
French (fr)
Other versions
CA2216696C (en
Inventor
Daniel J. Smith
Debashish Chakravarthy
Larry K. Keefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Akron
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2216696A1 publication Critical patent/CA2216696A1/en
Application granted granted Critical
Publication of CA2216696C publication Critical patent/CA2216696C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C08B15/05—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur
    • C08B15/06—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur containing nitrogen, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A polymeric composition capable of releasing nitric oxide comprises a polysaccharide including a nitric oxide-releasing N2O.cndot.
functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.
CA002216696A 1995-04-10 1996-04-10 Polysaccharide-bound nitric oxide-nucleophile adducts Expired - Fee Related CA2216696C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/419,424 1995-04-10
US08/419,424 US5691423A (en) 1992-08-24 1995-04-10 Polysaccharide-bound nitric oxide-nucleophile adducts
PCT/US1996/004899 WO1996032136A1 (en) 1995-04-10 1996-04-10 Polysaccharide-bound nitric oxide-nucleophile adducts

Publications (2)

Publication Number Publication Date
CA2216696A1 true CA2216696A1 (en) 1996-10-17
CA2216696C CA2216696C (en) 2009-01-06

Family

ID=23662207

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002216696A Expired - Fee Related CA2216696C (en) 1995-04-10 1996-04-10 Polysaccharide-bound nitric oxide-nucleophile adducts

Country Status (5)

Country Link
US (1) US5691423A (en)
EP (1) EP0822833A1 (en)
JP (2) JPH11503456A (en)
CA (1) CA2216696C (en)
WO (1) WO1996032136A1 (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200558B1 (en) * 1993-09-14 2001-03-13 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
CA2266908C (en) * 1996-09-27 2010-07-20 Joseph E. Saavedra O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US5962520A (en) * 1998-04-02 1999-10-05 The University Of Akron Hydrolytically unstable, biocompatible polymer
US6261594B1 (en) * 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
AU7101600A (en) * 1999-09-02 2001-03-26 Rice University Nitric oxide-producing hydrogel materials
US7052711B2 (en) 1999-09-02 2006-05-30 Rice University Nitric oxide-producing hydrogel materials
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
US6737447B1 (en) 1999-10-08 2004-05-18 The University Of Akron Nitric oxide-modified linear poly(ethylenimine) fibers and uses thereof
US7572374B2 (en) * 2000-04-13 2009-08-11 Transvivo, Inc. Anticoagulant and thrombo-resistant hollow fiber membranes for in-vivo plasmapheresis and ultrafiltration
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
SE0004026D0 (en) * 2000-11-03 2000-11-03 Peter Wiklund New use
JP2005501060A (en) * 2001-08-10 2005-01-13 ニトロメッド，インク． How to use sulfur-containing organic nitrate compounds
EP1436018A1 (en) * 2001-09-26 2004-07-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
EP1340772A1 (en) * 2002-02-28 2003-09-03 Nicox S.A. Nitro-derivatives of epoxyheparin
US7204940B2 (en) 2002-03-20 2007-04-17 Michigan Biotechnology Institute Conductive polymer-based material
CA2488230C (en) 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
WO2004012874A1 (en) 2002-08-02 2004-02-12 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Cross-linked nitric oxide-releasing polyamine coated substrates, compositions comprising same and method of making same
US6951902B2 (en) * 2002-08-16 2005-10-04 Michigan Biotechnology Institute Two dimensional polymer that generates nitric oxide
US20090136410A1 (en) * 2003-07-25 2009-05-28 Smith Daniel J Stabilization and ionic triggering of nitric oxide release
WO2005070008A2 (en) 2004-01-22 2005-08-04 The University Of Akron Polymer no donor predrug nanofiber coating for medical devices and therapy
EP1718603A4 (en) * 2004-02-09 2009-09-23 Noxilizer Inc Nitric oxide-releasing molecules
US7569559B2 (en) * 2004-02-09 2009-08-04 Noxilizer, Inc. Nitric oxide-releasing molecules
EP1732577B1 (en) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topical delivery of l-arginine to improve body and skin appearance
WO2005102282A1 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
CA2581939C (en) 2004-09-27 2013-01-08 Joseph A. Hrabie Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof
EP1700611A1 (en) * 2005-02-11 2006-09-13 NOLabs AB Device for treatment of disorders in the oral cavity, and manufacturing process for the same
MX2007009690A (en) 2005-02-11 2007-10-15 Nolabs Ab Device method, and use for treatment of neuropathy involving nitric oxide.
WO2006084914A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for gastric treatment and manufacturing process for the same
JP2008529626A (en) * 2005-02-11 2008-08-07 ノーラブズ エービー Device for treating dermatomycosis, in particular onychomycosis, and method for producing the same
WO2006084911A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Improved device for application of medicaments, manufacturing method therefor, and method of treatment
JP5042209B2 (en) 2005-03-24 2012-10-03 ノーラブズ エービー Cosmetic treatment with nitric oxide, apparatus for performing the treatment, and method for manufacturing the same
JP5274248B2 (en) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Nitric oxide releasing particles for nitric oxide therapy and biomedical applications
EP1741463A1 (en) 2005-07-05 2007-01-10 Millimed A/S A guiding and an embolization catheter
AU2006309212B2 (en) * 2005-10-31 2011-09-15 Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
JP2009518516A (en) * 2005-12-06 2009-05-07 アミュレット ファーマシューティカルズ インコーポレイティッド Nitric oxide releasing polymer
CN100441225C (en) * 2006-06-29 2008-12-10 上海交通大学 Amino-acid modified chitin nucleophic NO donor and its synthesis method
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US20100178319A1 (en) * 2007-03-27 2010-07-15 Lars Lindgren Topical Dermal Delivery Device For Nitric Oxide Delivery
JP5694964B2 (en) 2009-02-23 2015-04-01 ノクシライザー, インコーポレイテッドNoxilizer, Incorporated Gas sterilization apparatus and gas sterilization method
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
ES2607476T3 (en) 2009-06-24 2017-03-31 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
BR112012003804B1 (en) 2009-08-21 2019-02-19 Novan, Inc. Wound Dressing, Method to Form an Injury Dressing, and Wound Dressing Kit
EP2467127B1 (en) 2009-08-21 2023-08-02 Novan, Inc. Topical gels
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US20110251265A1 (en) * 2010-04-02 2011-10-13 Alberta Innovates - Technology Futures Polyamine-containing polymers and methods of synthesis and use
CN107021951B (en) 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC stimulators
WO2012004004A1 (en) * 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Nitric oxide delivering hydroxyalkyl starch derivatives
AU2011326241B2 (en) 2010-11-09 2016-11-17 Ironwood Pharmaceuticals, Inc. sGC stimulators
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2811515T3 (en) 2010-12-29 2021-03-12 Strategic Science & Tech Llc Erectile dysfunction treatment and other indications
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
ES2357601B1 (en) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF GLYCONAMINOGLYCAN DONORS OF NORTIC OXIDE AND ITS USE IN THE TREATMENT OF CHRONIC ULCERS.
US9034355B2 (en) 2011-02-24 2015-05-19 Colorado State University Research Foundation Materials for modulating biological responses and methods of making
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
BR112014000178A2 (en) 2011-07-05 2017-02-07 Novan Inc topical compositions
CN106117194A (en) 2011-12-27 2016-11-16 铁木医药有限公司 Can be used as 2 benzyls of SGC stimulant, 3 (pyrimidine 2 base) substituted pyrazoles
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
RS63108B1 (en) 2013-03-15 2022-04-29 Cyclerion Therapeutics Inc Sgc stimulators
KR102321169B1 (en) 2013-08-08 2021-11-02 노반, 인크. Topical compositions and methods of using the same
CN106304835A (en) 2013-12-11 2017-01-04 铁木医药有限公司 Sgc stimulant
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
EP3177262A4 (en) 2014-08-08 2018-04-18 Novan Inc. Topical emulsions
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
JP6624616B2 (en) 2014-09-17 2019-12-25 サイクレリオン・セラピューティクス，インコーポレーテッド sGC stimulant
US11439609B2 (en) * 2015-06-11 2022-09-13 The Regents Of The University Of Michigan Nitric oxide releasing PLGA microspheres for biomedical applications
WO2017151905A1 (en) 2016-03-02 2017-09-08 Novan, Inc. Compositions for treating inflammation and methods of treating the same
EP3442502A4 (en) 2016-04-13 2019-11-06 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
CA3029374A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Phosphorus prodrugs of sgc stimulators
JP2019524710A (en) 2016-07-07 2019-09-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド Solid form of SGC stimulant
WO2018067838A1 (en) 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
AU2018247167A1 (en) 2017-03-28 2019-09-26 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
US11883807B2 (en) 2017-04-11 2024-01-30 Colorado State University Research Foundation Functionalization of metal-organic frameworks
KR101909382B1 (en) 2017-05-19 2018-12-10 성균관대학교산학협력단 Vasodilation―inducing, gas―generating nanoparticles, preparation method and drug delivery system comprising the same
CN111836648A (en) * 2018-03-06 2020-10-27 北卡罗来纳大学查佩尔希尔分校 Nitric oxide releasing cyclodextrins as biodegradable antimicrobial scaffolds and related methods
CN113383019B (en) 2018-12-28 2023-11-17 北卡罗来纳大学教堂山分校 Nitric oxide releasing antimicrobial polymers and scaffolds made therefrom and methods relating thereto

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153094A (en) * 1959-06-10 1964-10-13 Du Pont Nitrosamine manufacture
NL145762B (en) * 1970-05-27 1975-05-15 Sandoz Ag PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION WITH HYPOTENSIVE / ANTIHYPERTENSIVE ACTION AND FORMED PREPARATION.
US3826832A (en) * 1970-06-08 1974-07-30 Sandoz Ag N-substituted amino-n-nitro-amino-acetonitriles as anti-anginal agents
US4265714A (en) * 1980-03-24 1981-05-05 General Electric Company Gas sensing and measuring device and process using catalytic graphite sensing electrode
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
DD211789A1 (en) * 1982-08-25 1984-07-25 Adw Ddr PROCESS FOR PREPARING POLYHYDROXYPOLYMER ESTERS, ESPECIALLY CELLULOSE ESTERS
JPS6125481A (en) * 1984-07-12 1986-02-04 Noguchi Kenkyusho Bead carrier for anchorage dependent cell culture
SE465907B (en) * 1984-11-01 1991-11-18 Nyegaard & Co As DIAGNOSTIC AGENT CONTENT AND PARAMAGNETIC METAL
US4638079A (en) * 1985-01-17 1987-01-20 Mallinckrodt, Inc. Inhibiting polymerization of ethylenically unsaturated monomers
US4708854A (en) * 1986-03-10 1987-11-24 The Dow Chemical Company Process for the removal of NO from fluid streams using a water-soluble polymeric chelate of a polyvalent metal
JPS63260971A (en) * 1987-04-20 1988-10-27 Hitachi Chem Co Ltd Radiation-curable pressure-sensitive adhesive composition
US4952289A (en) * 1988-05-09 1990-08-28 Aquanautics Corporation Macrocyclic amine complexes for ligand extraction and generation
US5094815A (en) * 1988-05-18 1992-03-10 Cornell Research Foundation, Inc. Photolytic interface for HPLC-chemiluminescence detection of non volatile N-nitroso compounds
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US4921683A (en) * 1989-06-20 1990-05-01 The Dow Chemical Company Nitric oxide abatement with polymeric cobalt(III) chelates
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
FR2653337B1 (en) * 1989-10-23 1992-02-07 Dow Corning Sa SUSTAINED RELEASE ELEMENT AND METHOD FOR MANUFACTURING THE SAME.
US5087671A (en) * 1990-06-25 1992-02-11 The Curators Of The University Of Missouri Polymers for scavenging nitrosating agents
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5087631A (en) * 1990-12-18 1992-02-11 Glaxo Inc. Oxathi(SIV)azol-5-one compounds
JPH0576588A (en) * 1991-03-29 1993-03-30 Jinkou Ketsukan Gijutsu Kenkyu Center:Kk Composite artificial blood vessel
WO1992018112A1 (en) * 1991-04-19 1992-10-29 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
WO1993007114A1 (en) * 1991-09-24 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
FR2686250A1 (en) * 1992-01-16 1993-07-23 Coletica INJECTABLE COMPOSITIONS CONTAINING SUSPENSION OF COLLAGEN - BASED MICROCAPSULES, THEIR BIOMEDICAL USE AND PHARMACEUTICAL COMPOSITIONS.
US5480644A (en) * 1992-02-28 1996-01-02 Jsf Consultants Ltd. Use of injectable biomaterials for the repair and augmentation of the anal sphincters
US5389675A (en) * 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents
WO1993020806A1 (en) * 1992-04-13 1993-10-28 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide/nucleophile complexes for the treatment of cancer
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
EP0713602B1 (en) * 1993-08-12 2002-07-17 Advanced Magnetics Incorporated Use of polysaccharide covered superparamagnetic oxide colloids
CA2106105C (en) * 1993-09-14 2008-03-18 Larry K. Keefer Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5650442A (en) * 1993-10-08 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers
US5482925A (en) * 1994-03-17 1996-01-09 Comedicus Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
US5519020A (en) * 1994-10-28 1996-05-21 The University Of Akron Polymeric wound healing accelerators

Also Published As

Publication number Publication date
AU5448396A (en) 1996-10-30
CA2216696C (en) 2009-01-06
JP2010111675A (en) 2010-05-20
AU695579B2 (en) 1998-08-13
JPH11503456A (en) 1999-03-26
EP0822833A1 (en) 1998-02-11
US5691423A (en) 1997-11-25
WO1996032136A1 (en) 1996-10-17

Similar Documents

Publication Publication Date Title
CA2216696A1 (en) Polysaccharide-bound nitric oxide-nucleophile adducts
CA2019410A1 (en) Liquid polymer composition, and method of use
ATE203157T1 (en) INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD
UA41989C2 (en) Pharmaceutical composition in form of gel for treating skin diseases and method for treating infected skin
RU94030735A (en) COMPOSITION MEMBRANE, METHOD FOR ITS PREPARATION AND METHOD FOR DIRECTED TISSUE REGENERATION WITH ITS APPLICATION
EP1234586A3 (en) Hepatoselective pharmaceutical actives
CA2095776A1 (en) Rapidly dispersable compositions containing polydextrose
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
DE2706135A1 (en) Thickening agent for excreted bowel contents and urine
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
DE69333556D1 (en) Injectable, ceramic compounds and processes for their production and use
GEP20012375B (en) Isothiazolones, Pharmaceutical Composition on Their Basis and Method for Obtaining the Same
CA2131830A1 (en) Soft resilient interocclusal dental appliance, method of forming same and composite for same
DE59410052D1 (en) USE OF NONA AND DECAPEPTIDES FOR THE PRODUCTION OF A MEDICINAL AGAINST AIDS
CA2258920A1 (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
CA2212519A1 (en) Process for the coating of objects with hyaluronic acid, derivatives thereof, and semisynthetic polymers
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
CA2157323A1 (en) Gepirone dosage form
CA2106105A1 (en) Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
IL115138A0 (en) Implantable polymer-containing molded articles for the administration of active substances to plants and processes for the preparation thereof
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
CA2143413A1 (en) Local Drug Delivery Film, for Periodontal Treatment
WO2002098464A3 (en) Liquid polymer composition for prevention and treatment of the oral cavity diseases
CA2189436A1 (en) Oral hygiene composition
CA2221900A1 (en) Use of trospium chloride and 2-component system for the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed